FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Slideshows|June 22, 2015
Shift Work and Metabolic Disorders
Author(s)Veronica Hackethal, MD
Diabetes, obesity, CVD-all have been linked to disruption of the day-night rhythm caused by shift work. More facts and some tips for your shift-weary patients, here.
Advertisement
Shift work is known to cause dangerous disruption in the circadian rhythms that regulate sleeping and waking. Sleep disturbance and associated sleepiness lead to poor concentration, absenteeism, accidents, errors, injuries, and fatalities. Shift work is also linked to metabolic disturbances that lead to chronic disease such as obesity, diabetes and hypertension. The slides above offer evidence for these connections and also some tips for primary care physicians to offer at-risk patients.
References:
- Brum MC, Filho FF, Schnorr CC, et al. Shift work and its association with metabolic disorders. Diabetol Metab Syndr. 2015;7:45. doi:10.1186/s13098-015-0041-4. eCollection 2015.
- Gangwisch JE, Malaspina D, Boden-Albala B, et al. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep. 2005;28:1289-1296.
- van Drongelen A1, Boot CR, Merkus SL, et al. The effects of shift work on body weight change-a systematic review of longitudinal studies. Scand J Work Environ Health. 2011;37:263-275. doi:10.5271/sjweh.3143. Epub 2011 Jan 18.
- Lin YC, Hsiao TJ, Chen PC, et al. Persistent rotating shift-work exposure accelerates development of metabolic syndrome among middle-aged female employees: a five-year follow-up. Chronobiol Int. 2009;26:740-755. doi:10.1080/07420520902929029.
- Pan A, Schernhammer ES, Sun Q, et al. Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women. PLoS Med. 2011;8:e1001141. doi:10.1371/journal.pmed.1001141. Epub 2011 Dec 6.
Advertisement
Related to this article
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
4
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
5